{"product_id":"me-vrio-analysis","title":"23andMe Holding Co. (ME): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs 23andMe Holding Co. (ME) truly built for long-term dominance? We subjected its core assets to the rigorous VRIO test - Value, Rarity, Inimitability, and Organization - to uncover the source of its competitive edge, or lack thereof. This distilled summary reveals the critical findings: are its strengths fleeting or fundamentally sustainable? Read on to see the definitive strategic verdict detailed in the full analysis below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 1. World-Leading Genetic \u0026amp; Phenotypic Database\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset that survived the Chapter 11 process, which is smart. This database is the engine room, and even after the July 2025 sale to the nonprofit TTAM Research Institute for $305 million, its value proposition remains intact, though the organizational goal has shifted. Let’s break down why this data trove is so hard to touch.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Scale and Depth of Genetic Information\u003c\/h3\u003e\n\u003cp\u003eThe value here is in the sheer scale of consented, de-identified data, which is crucial for finding statistically robust genetic links to disease targets. We are talking about over 15 million consented customers. This massive pool has generated over 4 billion health and trait data points, which is the fuel for any serious pharmaceutical or academic partnership. To be fair, this scale allows for a level of statistical power that smaller or newer players simply cannot match right now. It’s a tangible asset that TTAM Research Institute acquired to continue its research mission.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the dataset’s diversity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal consented customers: Over 15 million.\u003c\/li\u003e\n\u003cli\u003eTotal data points: Over 4 billion.\u003c\/li\u003e\n\u003cli\u003eNon-European ancestry participants: Over 3 million+.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Diversity Beyond the Usual\u003c\/h3\u003e\n\u003cp\u003eYes, the database is rare, but not just because of the total size. What makes it stand out, especially compared to public biobanks, is the diversity. Having over 3 million+ participants of non-European ancestry is a significant differentiator. Most legacy datasets skew heavily toward individuals of European descent, which limits the generalizability of drug targets. This diversity helps mitigate that bias, making the data more valuable for global health research. What this estimate hides is the longitudinal quality - the fact that many users have updated their data over years.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Decades and Billions to Replicate\u003c\/h3\u003e\n\u003cp\u003eReplicating this asset would be incredibly difficult, honestly. The imitability is high because you aren't just buying a list; you are buying the trust that led 15 million people to submit their DNA and health information. To build this from scratch today, a competitor would need decades to acquire the scale and diversity, plus billions in consumer acquisition and marketing costs. Plus, the new owner, TTAM, is a nonprofit, which changes the competitive dynamic entirely, focusing on research exploitation rather than direct profit motives.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Shift to Nonprofit Research Focus\u003c\/h3\u003e\n\u003cp\u003eThe organization aspect has seen a major shift. Historically, 23andMe Holding Co. was structured to balance consumer service with pharma partnerships. However, the July 2025 acquisition by TTAM Research Institute fundamentally reorients this. The organization is now explicitly focused on research exploitation, which is good for the data asset’s long-term utility in science, but perhaps less so for consumer-facing product velocity. TTAM has pledged to uphold existing privacy policies, which is a critical organizational commitment post-acquisition.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of the competitive implications based on the VRIO assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication for 23andMe (under TTAM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSupports high-value research partnerships.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique diversity, especially in non-European cohorts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh Difficulty\u003c\/td\u003e\n\u003ctd\u003eMassive consumer acquisition barrier to entry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes (New Focus)\u003c\/td\u003e\n\u003ctd\u003eStructure aligned for non-profit research monetization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe data asset itself is a massive, hard-to-replicate moat.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eEven with the recent market capitalization sitting around $89.24 million as of December 1, 2025, the underlying research asset remains a powerful, sustained advantage. If onboarding takes 14+ days, churn risk rises, but the data asset value is locked in.\u003c\/p\u003e\n\n\u003cp\u003eFinance: Draft a memo by Friday detailing the expected annual research services revenue run-rate under the TTAM structure, using Q3 FY25 revenue of $60.3 million as a baseline context for the prior operating model.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 2. Drug Target Identification \u0026amp; Validation Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The proven ability to use genetic evidence to identify and validate novel drug targets, demonstrated by identifying \u003cstrong\u003eover 40\u003c\/strong\u003e therapeutic programs with GSK under the exclusive term ending in \u003cstrong\u003eJuly 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe platform's value is further evidenced by clinical progression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAsset \u003cstrong\u003e23ME-00610\u003c\/strong\u003e, an anti-CD200R1 antibody, reached \u003cstrong\u003ePhase I\/IIa\u003c\/strong\u003e clinical trial stages.\u003c\/li\u003e\n\u003cli\u003eThe preliminary recommended Phase 2 dose for \u003cstrong\u003e23ME-00610\u003c\/strong\u003e is \u003cstrong\u003e1400 mg\u003c\/strong\u003e dosed every three weeks.\u003c\/li\u003e\n\u003cli\u003eThe hypothesis suggests drug targets based on human genetics are at least \u003cstrong\u003etwice as likely\u003c\/strong\u003e to become successful medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biopharma firms use genetics, but 23andMe’s scale gives it a higher hit rate for novel targets.\u003c\/p\u003e\n\u003cp\u003eStatistical evidence of scale:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Cohort Size (Study Example)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMore than 7.5 million\u003c\/strong\u003e individuals consented to research data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Customers with Data\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMore than 15 million\u003c\/strong\u003e customers with genotype and phenotype information.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic Associations Found (Asthma Example)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e652\u003c\/strong\u003e significant genetic associations for asthma.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the underlying scientific methods are known, but the proprietary data feed makes the application hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003eThe proprietary data advantage is quantified by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGenetic insights linking a drug target to disease are available for \u003cstrong\u003e60 percent more\u003c\/strong\u003e drug targets than from other resources due to scale.\u003c\/li\u003e\n\u003cli\u003eThe initial GSK collaboration involved a \u003cstrong\u003e$300 million\u003c\/strong\u003e equity investment, demonstrating perceived initial value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong, as evidenced by the continued therapeutic programs (like 23ME-00610) moving through clinical stages post-sale, despite a strategic shift to discontinue new development.\u003c\/p\u003e\n\u003cp\u003eOrganizational evidence includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe GSK exclusive target discovery period extension to \u003cstrong\u003eJuly 2023\u003c\/strong\u003e involved a \u003cstrong\u003e$50 million\u003c\/strong\u003e one-time payment.\u003c\/li\u003e\n\u003cli\u003eFollowing exclusivity, a non-exclusive data license with GSK was signed for a \u003cstrong\u003e$20 million\u003c\/strong\u003e upfront payment.\u003c\/li\u003e\n\u003cli\u003eThe company is actively exploring strategic opportunities for pipeline assets, including \u003cstrong\u003e23ME-00610\u003c\/strong\u003e, which is in \u003cstrong\u003ePhase I\/IIa\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the exclusive GSK term ended in \u003cstrong\u003eJuly 2023\u003c\/strong\u003e, but the platform's proven success still offers a near-term edge.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 3. Personal Genome Service (PGS) Customer Base \u0026amp; Brand Equity\n\u003c\/h2\u003e\n\u003cp\u003e\nThe Personal Genome Service (PGS) customer base and brand equity are foundational assets for 23andMe.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eConsumer Services revenue, which includes PGS, represented approximately \u003cstrong\u003e97%\u003c\/strong\u003e of total revenue in FY25 Q1, which was \u003cstrong\u003e\\$40 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eBrand recognition in health\/ancestry is top-tier, supported by having genotyped more than \u003cstrong\u003e14,000,000\u003c\/strong\u003e individuals as of February 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eBuilding trust to acquire the established user base took significant time and marketing history.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eThe core consumer business, including PGS, was acquired by TTAM Research Institute for \u003cstrong\u003e\\$305 million\u003c\/strong\u003e following bankruptcy proceedings.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained due to the installed base and established consumer trust, which was valued at the \u003cstrong\u003e\\$305 million\u003c\/strong\u003e acquisition price.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nKey quantitative data points related to the PGS customer base:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY25 Q1 Total Revenue: \u003cstrong\u003e\\$40 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY25 Q1 Consumer Services Revenue Share (including PGS): Approximately \u003cstrong\u003e97%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGenotyped Individuals (as of February 2024): More than \u003cstrong\u003e14,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAcquisition Price for Core Business (including PGS) by TTAM: \u003cstrong\u003e\\$305 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePeak Market Capitalization (prior to bankruptcy): Approximately \u003cstrong\u003e\\$6 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe value proposition is further evidenced by the structure of the business prior to the asset sale:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY24 Full Year Consumer Services Revenue Share: Approximately \u003cstrong\u003e92%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY24 Q4 Consumer Services Revenue Share: Approximately \u003cstrong\u003e99%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 4. Lemonaid Health Telehealth Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the regulatory and operational framework to offer direct-to-consumer health services, including the launch of the GLP-1 weight loss membership by the end of \u003cstrong\u003eAugust 2024\u003c\/strong\u003e via the platform. 23andMe initially invested \u003cstrong\u003e$400 million\u003c\/strong\u003e to acquire this infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many telehealth platforms exist, but this one is integrated with genetic insights, leveraging a database of approximately \u003cstrong\u003e13 million\u003c\/strong\u003e users who have consented to research as of August 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can buy or build similar platforms relatively easily. The strategic value was in the integration, not the platform itself.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Acquired for \u003cstrong\u003e$400 million\u003c\/strong\u003e in 2021, indicating its strategic importance for the end-to-end health vision. Following bankruptcy proceedings, the asset was subsequently sold for \u003cstrong\u003e$10 million\u003c\/strong\u003e in September 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a necessary utility for the integrated health strategy, not a unique differentiator on its own, as evidenced by the subsequent sale price relative to the acquisition cost.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eRelevant Financial\/Statistical Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Investment (Value)\u003c\/td\u003e\n\u003ctd\u003eHigh Cost\u003c\/td\u003e\n\u003ctd\u003eAcquisition price of \u003cstrong\u003e$400 million\u003c\/strong\u003e (25% cash, 75% stock).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration Scale (Rarity)\u003c\/td\u003e\n\u003ctd\u003eModerate\/Low\u003c\/td\u003e\n\u003ctd\u003ePlatform supports services for a customer base that generated \u003cstrong\u003e21%\u003c\/strong\u003e of total revenue from membership services in Q2 FY2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Goal (Organization)\u003c\/td\u003e\n\u003ctd\u003eHigh Importance, then Devalued\u003c\/td\u003e\n\u003ctd\u003eThe GLP-1 study associated with the platform aims to recruit \u003cstrong\u003e10,000\u003c\/strong\u003e participants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Restructuring Value\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eSubsequent sale price of \u003cstrong\u003e$10 million\u003c\/strong\u003e in September 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eThe GLP-1 membership launch occurred as the company reported Q2 Fiscal 2025 total revenue of \u003cstrong\u003e$44 million\u003c\/strong\u003e, down \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q2 FY2025 were \u003cstrong\u003e$84 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e17%\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 5. 23andMe+ Membership Recurring Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMembership services revenue represented \u003cstrong\u003e21%\u003c\/strong\u003e of total revenue for Q2 FY2025 (ended September 30, 2024), compared to \u003cstrong\u003e9%\u003c\/strong\u003e in the prior year quarter.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for Q2 FY2025 was \u003cstrong\u003e$44 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMembership services revenue more than doubled compared to the prior year quarter.\u003c\/li\u003e\n\u003cli\u003eThe 23andMe+ subscription price increased from \u003cstrong\u003e$29\u003c\/strong\u003e to \u003cstrong\u003e$69\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company launched a GLP-1 weight-loss telehealth membership with \u003cstrong\u003ethousands enrolled\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 FY2025 (Ended Sept 30, 2024)\u003c\/th\u003e\n\u003cth\u003eQ2 FY2024 (Prior Year Quarter)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembership Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003eLoss of \u003cstrong\u003e$33 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLoss of $45 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe offering includes access to over \u003cstrong\u003e30\u003c\/strong\u003e Polygenic Risk Score (PRS) reports as of Q1 FY25.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRetention is dependent on continuous delivery of new insights, such as the Emotional Eating PRS.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company ended September 30, 2024, with cash and cash equivalents of \u003cstrong\u003e$127 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's financial statements included a going concern disclosure requiring additional liquidity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe success is tied to the continuous release of new reports, such as the Emotional Eating PRS.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 6. Proprietary Polygenic Risk Score (PRS) Algorithms\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The scientific models translate raw genetic data into actionable health risk reports, with \u003cstrong\u003eover 30 reports\u003c\/strong\u003e available based on polygenic risk models as of the period leading up to early 2025. A recent example is the Bipolar Disorder report, launched in June 2024 for 23andMe+ Premium members.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While PRS is a general field, 23andMe’s specific, validated models are unique due to the scale and diversity of their proprietary dataset. As of February 2024, the company had genotyped more than \u003cstrong\u003e14,000,000\u003c\/strong\u003e individuals. Approximately \u003cstrong\u003e80%\u003c\/strong\u003e of these customers consent to participate in research, forming the training cohort.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High difficulty; the models are complex, proprietary statistical constructs requiring extensive data training. The Bipolar Disorder PRS, for instance, was developed using data from the largest genome-wide association study to date for that condition, identifying over \u003cstrong\u003e300 genetic variants\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The PRS algorithms are central to the value proposition for 23andMe+ members, positioning them as a core Research \u0026amp; Development asset, despite the company filing for Chapter 11 bankruptcy in March 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained advantage is derived as the algorithms are continuously refined by the unique, large-scale, and increasingly diverse data they process from consented participants.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Genotyped Individuals (as of Feb 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14,000,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal customer base used for research pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Consent Rate for Research\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePercentage of customers consenting to participate in research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal PRS-based Reports Offered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of reports powered by polygenic risk models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBipolar Disorder PRS Variants Used (Example)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,612\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of variants selected for one ancestry group in the Bipolar Disorder model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBipolar Disorder Variants Identified in GWAS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of genetic variants associated with Bipolar Disorder found in the underlying study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe complexity and scale of the underlying data and model development are illustrated by the following components:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Bipolar Disorder PRS model incorporated genetic features alongside age, sex, age interaction terms, and the first \u003cstrong\u003eten\u003c\/strong\u003e genetic principal components (PCs) to account for population substructure.\u003c\/li\u003e\n\u003cli\u003eThe development of PRS models involves multiple steps, including 'clumping and thresholding' to select risk variants across different populations (e.g., European, African, East Asian, South Asian, and Latino).\u003c\/li\u003e\n\u003cli\u003eThe company has collaborated on research that utilizes data from over \u003cstrong\u003e50,000\u003c\/strong\u003e consented customers for specific studies like the AFFECT study on mood disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 7. In-House Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated ability to move drug candidates, like 23ME-00610, through early-stage clinical trials (Phase 1\/2a completed enrollment in \u003cstrong\u003eApril 2024\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotech firms do this, but 23andMe couples it directly with genetic target identification, leveraging a database of approximately \u003cstrong\u003e15 million\u003c\/strong\u003e individuals with genotype and phenotype data, of which $\\sim$\u003cstrong\u003e80%\u003c\/strong\u003e consent to participation in research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires specialized regulatory and medical expertise that is not easily replicated overnight.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This capability is crucial for the therapeutics arm, which remains a focus for the new nonprofit entity; the assets were acquired for \u003cstrong\u003e$305 million\u003c\/strong\u003e in a bankruptcy sale, with the new entity pledging to invest \u003cstrong\u003e$84 million\u003c\/strong\u003e in operations over the next year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; success in later-stage trials will determine long-term advantage.\u003c\/p\u003e\n\u003cp\u003eKey metrics supporting the in-house execution capability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenotyped Customer Base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15 million\u003c\/strong\u003e+\u003c\/td\u003e\n\u003ctd\u003eAs of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Research Consent Rate\u003c\/td\u003e\n\u003ctd\u003e$\\sim$\u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e23ME-00610 Phase 1\/2a Enrollment Completion\u003c\/td\u003e\n\u003ctd\u003eCompleted\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Price for Core Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$305 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBankruptcy Sale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTAM Nonprofit Initial Operational Pledge\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$84 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver the next year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe clinical pipeline progress includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e23ME-00610\u003c\/strong\u003e: Anti-CD200R1 antibody, presented data from neuroendocrine and ovarian cancer cohorts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e23ME-01473\u003c\/strong\u003e: Dual-mechanism natural killer (NK) cell activator, dosing initiated for Phase 1 clinical trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context related to the Therapeutics division prior to the asset sale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch services revenue accounted for approximately \u003cstrong\u003e3%\u003c\/strong\u003e of total revenue for FY25 Q1 (ended June 30, 2024).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA loss for FY25 Q1 was \u003cstrong\u003e$35 million\u003c\/strong\u003e, an improvement from a loss of \u003cstrong\u003e$50 million\u003c\/strong\u003e in the prior year period, partially due to lower R\u0026amp;D expenses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 8. Data Governance and Privacy Framework (Post-Sale)\n\u003c\/h2\u003e\n\u003cp\u003eThe post-sale data governance framework under TTAM Research Institute (TTAM) is a critical component of the asset transfer, directly addressing the sensitivity of the genetic data trove.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The commitment by the acquirer, TTAM Research Institute, to adhere to existing privacy policies \u003cstrong\u003ein perpetuity\u003c\/strong\u003e, which is critical for maintaining the trust needed to keep the database active, which previously comprised over \u003cstrong\u003e14,000,000\u003c\/strong\u003e genotyped individuals as of February 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; privacy compliance is a baseline requirement, but the explicit nonprofit commitment by TTAM is a unique structural feature now following the bankruptcy sale for \u003cstrong\u003e$305 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; it’s a legal and policy commitment, not a proprietary technology.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The entire sale process was heavily influenced by securing a buyer committed to privacy, making this a key organizational mandate for the successor. TTAM is required to seek consent from each former and current customer before accessing genetic data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a necessary condition for operation, not a source of outperformance.\u003c\/p\u003e\n\n\u003cp\u003eThe numerical and structural elements underpinning this framework are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Purchase Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$305 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition price paid by TTAM Research Institute\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Database Size (Pre-Sale Context)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e14,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIndividuals genotyped as of February 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 Data Breach Impact\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7 million\u003c\/strong\u003e users\u003c\/td\u003e\n\u003ctd\u003eNumber of users whose data was stolen in the October 2023 breach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Sale Identity Protection\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTwo years\u003c\/strong\u003e free monitoring\u003c\/td\u003e\n\u003ctd\u003eExperian identity theft monitoring offered by TTAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Opt-In Rate (Historical)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePercentage of customers who consented to data use for research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Deletions (During Bankruptcy)\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e1.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNumber of customers who deleted accounts since bankruptcy proceedings began\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific organizational and policy mandates established for the post-sale environment include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAdherence to 23andMe's existing privacy policies \u003cstrong\u003ein perpetuity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEstablishment of a Consumer Privacy Advisory Board within \u003cstrong\u003e90 days\u003c\/strong\u003e of closing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePublication of \u003cstrong\u003eannual\u003c\/strong\u003e privacy reports made available to State Attorneys General upon request.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRequirement for TTAM to seek \u003cstrong\u003econsent from each\u003c\/strong\u003e former and current customer before accessing genetic data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCommitment not to sell or transfer genetic data in a subsequent change of control unless the recipient adopts TTAM's privacy policies and complies with all laws.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003e23andMe Holding Co. (ME) - VRIO Analysis: 9. Total Health\/Biomarker Integration Service\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to combine raw genetic data with actionable lab results, such as the Total Health service offering bi-annual lab tests for \u003cstrong\u003e55+\u003c\/strong\u003e key blood biomarkers alongside genetic reports.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; few competitors offer this deep, integrated sequencing plus longitudinal blood monitoring. The pilot program offered Nightingale's Remote Health Check blood test free of charge to up to \u003cstrong\u003e5,000\u003c\/strong\u003e 23andMe+ Premium and Total Health members.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires integrating lab partnerships (like the Nightingale Health pilot) with the core genetic platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This represents the company’s highest-value consumer offering, designed to drive recurring engagement. Membership services revenue grew to represent \u003cstrong\u003e21%\u003c\/strong\u003e of total revenue in Q2 FY25, up from \u003cstrong\u003e9%\u003c\/strong\u003e in the prior year quarter.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; success relies on continuously adding new, valuable biomarkers and insights.\u003c\/p\u003e\n\n\u003cp\u003eThe integration of blood biomarker data with genetic information is a key strategic focus, as evidenced by the collaboration with Nightingale Health.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eService Component\u003c\/td\u003e\n\u003ctd\u003eMetric\/Data Point\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker Integration Pilot\u003c\/td\u003e\n\u003ctd\u003eCohort Size (Up to)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5,000\u003c\/strong\u003e Members\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Health Offering\u003c\/td\u003e\n\u003ctd\u003eKey Blood Biomarkers Tracked\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55+\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription Revenue Share (Q2 FY25)\u003c\/td\u003e\n\u003ctd\u003eMembership Services Revenue % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription Revenue Share (Q2 FY24)\u003c\/td\u003e\n\u003ctd\u003eMembership Services Revenue % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Total Health service is designed to provide a comprehensive view, combining genetic sequencing with longitudinal monitoring.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eThe service is designed to help customers track and improve their health with regular blood testing using Nightingale Health's technology.\u003c\/li\u003e\n\u003cli\u003eThe integration aims to improve the accuracy of risk assessments for various health conditions.\u003c\/li\u003e\n\u003cli\u003eThe company added a Biological Age feature to the Total Health offering to help members monitor physiological aging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Pro-Forma Cash Flow Statement for TTAM Research Institute (Projected)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReflecting the \u003cstrong\u003e$305 million\u003c\/strong\u003e acquisition cost and projected revenue from the PGS business for the next two quarters (Q4 FY25 and Q1 FY26).\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow Item\u003c\/td\u003e\n\u003ctd\u003eQ4 Fiscal Year 2025 (Projected)\u003c\/td\u003e\n\u003ctd\u003eQ1 Fiscal Year 2026 (Projected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCash Flows from Operating Activities\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected PGS Business Revenue (Proxy: Consumer Services Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Operating Activities (Excluding Acquisition)\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNot Provided\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNot Provided\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCash Flows from Investing Activities\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition of 23andMe Holding Co. (TTAM Purchase Price)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($305,000,000)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Investing Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($305,000,000)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNet Change in Cash and Cash Equivalents\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNot Provided\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNot Provided\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cem\u003eNote: The acquisition closing was approved in July 2025, thus the \u003cstrong\u003e$305,000,000\u003c\/strong\u003e outflow is projected in Q4 FY25. PGS Business Revenue is projected based on the latest reported Consumer Services Revenue figures from FY25 Q3 of \u003cstrong\u003e$39.6 million\u003c\/strong\u003e.\u003c\/em\u003e\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516206768277,"sku":"me-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/me-vrio-analysis.png?v=1740140489","url":"https:\/\/dcf-model.com\/fr\/products\/me-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}